BUSINESS
Indegene acquires BioPharm to boost AI-powered pharma marketing
The deal, executed through Indegene’s US subsidiary ILSL Inc., aims to strengthen the company’s omnichannel and media offerings by integrating BioPharm’s precision marketing expertise with Indegene’s data and analytics platforms.
BUSINESS
Generic drug approvals in US poised for a rise, Indian drugmakers continue to dominate
USFDA approvals are vital for India, which exported $10 billion worth of generic medicines to US in FY25
BUSINESS
Somerset Indus Capital Partners exits Apex Hospitals with 4x return
Somerset’s investment in Apex began in May 2019, during which the hospital group tripled its revenue and doubled its workforce, expanding access to quality healthcare across Tier 2 and Tier 3 cities in Rajasthan.
BUSINESS
Fertility services firm Gaudium IVF re-files IPO with Sebi with a higher OFS portion
The offer now comprises a fresh issue of up to 1.13 crore equity shares and an offer for sale (OFS) of up to 94.94 lakh shares by Dr. Khanna.
BUSINESS
Fresh Trump tariffs, what is at stake for Indian pharma, and the playbook to survive
Imported generics have so far managed to escape Trump’s glare likely due to their critical role in keeping US healthcare costs in check. However, Indian pharma is not waiting for the axe to fall, and experts say a multi-pronged defence strategy by key players is already in motion.
BUSINESS
Lupin to acquire VISUfarma for euro 190 million, expanding European specialty footprint
In 2024, VISUfarma, backed by GHO Capital, reported a revenue of 48.1 million. It operates in all major European markets, including Italy, the UK, Spain, Germany, and France
BUSINESS
Sun Pharma may face tariff turbulence in US but HSBC sees limited earnings risk
HSBC outlines several mitigation strategies for Sun Pharma, including shifting manufacturing to CDMO partners with US-based plants.
BUSINESS
Trump’s 100% drug tariff: A mixed bag for India’s CRDMO industry
“Few Indian pharma companies with exposure to non-U.S. domiciled branded formulation or innovator drug companies, who in turn export to the U.S., may face challenges,” said Deepak Jotwani, VP & Sector Head, ICRA.
BUSINESS
Generic medicines exempted from Trump’s 100% pharma tariffs, but uncertainty continues
While generic drugs are exempted from the latest action, companies still face uncertainty over tariffs due to an investigation by the US government under Section 232 to see whether pharma imports pose a threat to national security.
BUSINESS
Greying India fuels adult diaper market boom, homegrown Friends leads the way
Unlike baby diapers, dominated by FMCG giants such as P&G, Unicharm and Kimberly-Clark, the Rs 1,200-crore adult diaper segment is commanded by Friends with over a 50% market share
BUSINESS
Alkem launches pertuzumab biosimilar in India for treatment of breast cancer
In the pivotal phase 3 clinical trial, Alkem’s pertuzumab biosimilar, developed by its biotech subsidiary, demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator, the company said in a press release.
BUSINESS
Senior care market poised to triple in a decade, turning the space into the next big investment idea
Rising life expectancy, smaller families and growing willingness among seniors to spend on care are creating conditions for a market that could expand several times over in the coming decade.
BUSINESS
Stryker expands India R&D with new innovation centre in Bengaluru
The Whitefield centre will house cross-functional teams and advanced labs focused on robotics, artificial intelligence, digital innovation, and product security, the company said Thursday.
BUSINESS
Dr. Agarwal’s says merger valuation structured through fair and transparent process
The swap ratio—23 AHCL shares (Re 1 face value) for every 2 AEHL shares (Rs 10 face value)—was based on independent valuations by PwC and Bansi Mehta & Co., using globally accepted methods and market price trends, says company
BUSINESS
Bayer goes big on prenatal nutrition, eyes bigger share of India’s consumer health pie
While leveraging enduring appeal of legacy brands such as Saridon and Supradyn, Bayer is also aggressively pushing into India’s Rs 40,000–45,000 crore consumer health market
BUSINESS
Hospitals versus health insurers: Why patients are paying the price
Star Health alone logged 13,300 complaints in FY24, over 10,000 of which were claim-related
BUSINESS
Dr Reddy’s launches novel acid blocker Tegoprazan in India to tap $1 billion market
The rollout follows Dr. Reddy’s exclusive licensing deal with South Korea’s HK inno.N Corp. in 2022 to commercialize Tegoprazan in India and select emerging markets.
BUSINESS
India revokes Novartis' patent for blockbuster heart drug
Vymada is widely prescribed for hypertension and heart failure. For Novartis, the drug is a major revenue driver, generating $7.8 billion in global sales last year
BUSINESS
Brooks Labs looks to exit carbapenem JV, OneSource may buy stake
This move could provide a significant cash infusion for Brooks, which holds a 49% stake in the joint venture with Steriscience Specialties Pvt. Ltd.
BUSINESS
No mandatory relabelling of pre-revised GST stock, NPPA offers ease of compliance to industry
The National Pharmaceutical Pricing Authority (NPPA) clarified that companies can continue selling pre-GST stock without re-stickering, provided they ensure price compliance at the retail level through revised price lists and public communication.
BUSINESS
Apollo Hospitals to acquire IFC stake in AHLL for Rs 1,254 crore; announces Rs 573 crore oncology investment in Gurugram
AHLL consists primary care and diagnostics, birthing & women’s Health (Apollo Cradle), ambulatory care centers, dialysis & dental networks.
BUSINESS
Genomics major lllumina bets on India to power affordable innovation amid global headwinds
"India is not just a cost center—it’s becoming a core innovation engine for us," said Ankur Dhingra, Chief Financial Officer of Illumina told Moneycontrol.
BUSINESS
Dr. Reddy's acquires J&J's Stugeron brand for $50.5 million
The acquisition is a strategic move to strengthen Dr. Reddy's Central Nervous System (CNS) portfolio and expand into the anti-vertigo segment.
BUSINESS
GST rate cut to spur broader access and market growth of Indian pharma market
The sector, which recorded an 8.7% value growth in August 2025, is now bracing for a broader transformation in pricing, access, and patient volumes.
